Effect of intravenous injection of antagomiR-1 on brain ischemia
- 9 Downloads
Stroke is one of the leading causes of death in the world, but the underlying molecular mechanism of this disease remains elusive, thus it will be great challenges to finding appropriate protection. MicroRNAs are short, single-stranded, non-coding RNAs and recent studies have shown that they are aberrantly expressed in ischemic condition. Due to the fact that miR-1 has harmful effects on neural damages during brain ischemia, limited miR-1 has been proven to be protective in middle cerebral artery occlusion (MCAO). Here, the possible positive effect of intravenous injection of antagomiR-1 as a post-ischemic treatment on neurological deficits, infarct volume, brain edema and blood–brain barrier (BBB) permeability was evaluated. The rats were divided randomly into three experimental groups, each with 21 animals. MCAO surgery was performed on all groups and one hour later, 0.1 ml normal saline, 0.1 ml rapamycin and 300 pmol/g miR-1 antagomir (soluble in 0.1 ml normal saline), were injected intravenously into control, positive control and treatment group, respectively. After 24 h, neurologic deficits score, infarct volume, brain edema and BBB permeability were measured. The results indicated that post-treatment with miR-1 antagomir significantly improved neurological deficits and reduced infarction volume, brain edema, and BBB permeability. These data proved that there is a positive effects of antagomiR-1 on ischemic neuronal injury and neurological impairment. Due to the fact that microRNAs are able to protect the brain, it would be a promising therapeutic approach to stroke treatment.
KeywordsmiR-1 AntagomiR Stroke NDS Edema BBB Infarct volume
This work was performed as a PhD project supported financially by Department of Biology of Islamic Azad University-Zanjan, Faculty of life Sciences and biotechnology of Shahid Beheshti University, and Council for Stem Cell Sciences and Technologies. We also thank Dr Salma Ahmadloo for reviewing our research paper.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All the international, national, and/or institutional applicable guidelines for the care and use of animals were followed. All the animal procedures performed in this research were in accordance with the ethical standards of the institution at which the study was conducted. This article does not contain any studies performed on human participants by any of the authors.
- 1.Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J (2004) Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35(6):1490–1497CrossRefGoogle Scholar
- 2.Thomalla G, Sobesky J, Köhrmann M, Fiebach JB, Fiehler J, Weber OZ, Kruetzelmann A, Kucinski T, Rosenkranz M, Röther J, Schellinger PD (2007) Two tales: hemorrhagic transformation but not pa.renchyml hemorrhage after thrombolysis is related to severity and duration of ischemia-MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 38(2):313–318CrossRefGoogle Scholar